Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Paclitaxel, Pembrolizumab in patients with High-Grade Serous Fallopian Tube Cancer.
The European Medicines Agency (EMA) has authorized pembrolizumab in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 with a CPS >= 1 and who have received one or two prior systemic treatment regimens.
This statement is based on a regulatory approval from the European Medicines Agency:
KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumours express PD-L1 with a CPS >= 1 and who have received one or two prior systemic treatment regimens.